ASX News

Activities Report and Sales Note to Accompany Appendix 4C

Melbourne (Australia) – 27th July 2020. Telix Pharmaceuticals provides its Activities Report and Appendix 4C for the quarter ending 30th June 2020 and a Q2 2020 sales update

Telix Pharmaceuticals Limited is pleased to provide its Activities Report and Appendix 4C for the quarter ending 30th June 2020 and a Q2 2020 sales update for its prostate cancer imaging product, the TLX591-CDx kit (Kit for the preparation of 68Ga-PSMA-11 Injection).

To read full media release please click here.